Amylyx Pharmaceuticals (AMLX) Other Non Operating Income (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted Other Non Operating Income of -$53000.0 for Q2 2026, up 29.33% on a QoQ basis from -$75000.0 in Q1 2026, and up 90.29% year-over-year from -$27851.8 in Q2 2025.
Powered by 
Analysis
Amylyx Pharmaceuticals (AMLX) Other Non Operating Income (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals has reported Other Non Operating Income for 6 years, with the latest figure at -$53000.0 in Q2 2026.
- On a quarterly basis, Other Non Operating Income rose 90.29% year-over-year to -$53000.0 in Q2 2026; TTM through Jun 2026 was $3.5 million, a 52.99% decrease from a year earlier, with the FY2025 full-year figure at $2.7 million, down 61.35% from the prior year.
- Other Non Operating Income was -$53000.0 for Q2 2026 at Amylyx Pharmaceuticals, up from -$75000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $8.4 million in Q4 2024, with the low at -$747000.0 in Q1 2024.
- Average Other Non Operating Income over 5 years is $468944.4, with a median of -$111000.0 recorded in 2023.
- The sharpest annual moves came in 2023 and 2024: Other Non Operating Income slumped 1278.95% in 2023, then soared 4826.32% in 2024.
- Over 5 years, Other Non Operating Income stood at -$689000.0 in 2022, then surged by 124.82% to $171000.0 in 2023, then jumped by 4826.32% to $8.4 million in 2024, then sank by 55.03% to $3.8 million in 2025, then plunged by 101.4% to -$53000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$53000.0 (Q2 2026), -$75000.0 (Q1 2026), and $3.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn |
| 10 | Amylyx Pharmaceuticals | 3.69 Bn | 3.69 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -53,000.00 |
| Mar 31, 2026 | -75,000.00 |
| Dec 31, 2025 | 3.79 Mn |
| Sep 30, 2025 | -180,000.00 |
| Jun 30, 2025 | -546,000.00 |
| Mar 31, 2025 | -335,000.00 |
| Dec 31, 2024 | 8.42 Mn |
| Sep 30, 2024 | -141,000.00 |
| Jun 30, 2024 | -483,000.00 |
| Mar 31, 2024 | -747,000.00 |
| Dec 31, 2023 | 171,000.00 |
| Sep 30, 2023 | -488,000.00 |
| Jun 30, 2023 | -81,000.00 |
| Mar 31, 2023 | -262,000.00 |
| Dec 31, 2022 | -689,000.00 |
| Sep 30, 2022 | 199,000.00 |
| Jun 30, 2022 | -42,000.00 |
| Mar 31, 2022 | -19,000.00 |
| Dec 31, 2021 | -59,000.00 |
| Sep 30, 2021 | -227,000.00 |